ESR1 and breast carcinoma: The therapeutic potential of this field was realized relatively early on in the 1970s when Jensen and Craig Jordan demonstrated that an anti-estrogen called tamoxifen could be used to treat women with breast cancer in an ER-dependent manner [28].